Updates in Colorectal Cancer Management: Insights from ASCO GI

Dr. Patel and Dr. Gong cover key findings and takeaways from recent colorectal cancer studies, including BREAKWATER, COMMIT, STELLAR-303, ALASCCA, CHALLENGE, and ATOMIC.

BREAKWATER evaluates first-line targeted therapy combinations in BRAF V600E–mutant metastatic CRC, demonstrating improved response rates and progression-free survival with the addition of encorafenib-based regimens.

COMMIT investigates the role of immunotherapy with or without chemotherapy in dMMR metastatic CRC, helping clarify whether upfront chemotherapy adds benefit to checkpoint blockade in this population.

STELLAR-303 examines a novel therapeutic option in refractory CRC, comparing a new agent against standard therapies and showing modest survival benefit in heavily pretreated patients.

ALASCCA assesses the impact of adjuvant low-dose aspirin in biomarker-selected CRC patients, suggesting improved disease-free survival in patients with PI3K pathway alterations.

CHALLENGE evaluates structured exercise interventions in the post-treatment setting, demonstrating that increased physical activity is associated with improved disease-free survival and overall outcomes.

ATOMIC explores the addition of immunotherapy to standard adjuvant chemotherapy in resected dMMR CRC, supporting a potential shift toward incorporating checkpoint inhibitors in earlier-stage disease.